Carlo Hatem, MD
Critical Care Medicine · El Paso, TXNPI 1295814705
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,892 of the $10,562 with a category attached, or 74.7%. 42 manufacturers reported payments, led by Intuitive Surgical at 24.5% of the total. Reporting peaked in 2024 at $4,025 and has fallen 64.3% since, to $1,438 in 2025. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $28.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$588
- Regeneron Healthcare Solutions, Inc.$535
- Mylan Specialty L.p.$374
- plus $3K from 36 others
Across 188 payments — averaging $8250.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$784K
- AstraZeneca$449K
- Teva Pharmaceuticals USA, Inc.$59K
- Astrazeneca UK Limited$47K
- CSL Behring$41K
- Sanofi US Services Inc.$38K
- plus $133K from 6 others
What the payments were for
- Travel & lodging$1,09010%
- Food & beverage$7,89275%
- Education$1,58015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $2,590 |
| AstraZeneca(2 entities) | 82 | $1,956 |
| GSK | 88 | $1,396 |
| Boehringer Ingelheim | 23 | $588 |
| Regeneron Healthcare Solutions, Inc. | 24 | $535 |
| Mylan Specialty L.p. | 20 | $374 |
| Pulmonx Corporation | 4 | $349 |
| Grifols USA, LLC | 15 | $284 |
| Novartis | 13 | $275 |
| Sanofi | 12 | $235 |
| Actelion Pharmaceuticals US, Inc. | 8 | $189 |
| Viatris Specialty LLC | 8 | $187 |
| Johnson & Johnson | 2 | $140 |
| Sirtex Medical Inc | 1 | $130 |
| Inspire Medical Systems, Inc. | 2 | $120 |
| Genentech USA, Inc. | 6 | $109 |
| Amgen | 5 | $96 |
| Insmed, Inc. | 6 | $94 |
| Penumbra, Inc. | 1 | $91 |
| Gilead | 5 | $73 |
| Abbott | 1 | $65 |
| Mallinckrodt Hospital Products Inc. | 3 | $52 |
| Baxter Healthcare | 3 | $50 |
| United Therapeutics Corporation | 2 | $49 |
| Philips North America LLC | 2 | $46 |
| Tactile Systems Technology Inc | 2 | $44 |
| Verona Pharma, Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 4 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Biogen | 1 | $37 |
| La Jolla Pharmaceutical Company | 1 | $36 |
| AbbVie | 2 | $36 |
| Merck | 2 | $33 |
| Electromed, Inc. | 2 | $32 |
| Inogen, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Pfizer | 1 | $18 |
| Liquidia Technologies, Inc. | 1 | $18 |
| Eurofins Viracor, LLC | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,554
- FASENRA$604
- AIRSUPRA$490
- BREZTRI$424
- TEZSPIRE$424
- CHARTIS CATHETER$254
- ZEPHYR DELIVERY CATHETER$254
- ZEPHYR ENDOBRONCHIAL VALVE$254
- PULMONX CHARTIS TABLET CONSOLE$254
- SIR-Spheres Microspheres$130
- BEVESPI AEROSPHERE$114
- Inspire$107
- Monarch Platform$106
- TRELEGY ELLIPTA$103
How this compares
$10,562 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 80 | $969,403 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 369 | $403,241 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $93,154 |
| XolairOmalizumab | 22 | $91,619 |
| Breo ElliptaFluticasone/Vilanterol | 129 | $90,993 |
| Ambrisentan | 12 | $85,014 |
| Fasenra PenBenralizumab | 12 | $72,813 |
| Spiriva RespimatTiotropium Bromide | 67 | $65,444 |
| NucalaMepolizumab | 12 | $50,618 |
| Pirfenidone | 16 | $40,568 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $25,423 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 131 | $25,044 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $22,516 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $15,149 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $12,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $588 | $1,049,997168 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $1,396 | $583,212548 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,956 | $115,670151 claims |
| PfizerEliquis | $18 | $9,54516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in El Paso
- Hector PayanEl Paso$245K
- Juan FernandezEl Paso$33K
- Adolfo AnchondoEl Paso$12K
- Eugenio ArmendarizEl Paso$8K
- Steven DavidoffPlano$364K
- William BartekAustin$284K
- Edwin ParsleyHouston$283K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.